TABLE 2. Baseline Biochemical Characteristics of Study Patients

Group and CharacteristicIopamidol-370 GroupIodixanol-320 GroupP*
Data are presented as mean±SD where appropriate.
*t test.
Total population, n204210
    Predose SCr, mg/dL1.46±0.361.44±0.410.64
    Predose eGFR, mL/min per 1.73 m249.3±11.650.2±13.00.45
Patients without diabetes mellitusn=126n=118
    Predose SCr, mg/dL1.40±0.301.34±0.330.14
    Predose eGFR, mL/min per 1.73 m250.7±10.952.3±12.30.28
Patients with diabetes mellitus, n7892
    Predose SCr, mg/dL1.56±0.431.57±0.470.80
    Predose eGFR, mL/min per 1.73 m247.1±12.447.5±13.40.81
No pretreatment with NAC, n125121
    Predose SCr, mg/dL1.47±0.361.47±0.380.94
    Predose eGFR, mL/min per 1.73m249.8±11.849.5±12.90.85
Pretreatment with NAC, n7989
    Predose SCr, mg/dL1.45±0.361.42±0.450.57
    Predose eGFR, mL/min per 1.73 m248.6±11.451.3±13.20.16
Diagnostic cardioangiography, n123128
    Predose SCr, mg/dL1.46±0.371.44±0.430.70
    Predose eGFR, mL/min per 1.73 m249.2±11.549.9±13.20.65
PCI, n8182
    Predose SCr, mg/dL1.47±0.341.46±0.390.81
    Predose eGFR, mL/min per 1.73 m249.6±11.850.8±12.80.52